Boryung Pharm Total Assets
Boryung Pharm total assets. Based on the latest financial reports, Boryung Pharm (003850) holds total assets worth ₩1.36 Trillion KRW (≈ $918.96 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 003850 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Boryung Pharm (2009–2024)
Total assets of Boryung Pharm from 2009 to 2024. This chart illustrates how Boryung Pharm's total assets have evolved over time, based on quarterly financial data. See Boryung Pharm stock quote for real-time trading data and today's change.
Boryung Pharm - Asset Composition Analysis
Boryung Pharm Total Assets Breakdown (December 2024)
Boryung Pharm total assets breakdown as of December 2024. Boryung Pharm's total assets of ₩1.36 Trillion consist of 54.3% current assets and 45.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 16.1% |
| Accounts Receivable | ₩185.78 Billion | 16.0% |
| Inventory | ₩229.30 Billion | 19.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩151.09 Billion | 13.0% |
| Goodwill | ₩3.96 Billion | 0.3% |
Asset Composition Trend (2009–2024)
This chart illustrates how Boryung Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Boryung Pharm (003850) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boryung Pharm's current assets represent 54.3% of total assets in 2024, a decrease from 60.7% in 2009.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, up from 0.7% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 19.7% of total assets.
Boryung Pharm Competitors by Total Assets
Key competitors of Boryung Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Boryung Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 1.80 | 2.57 |
| Quick Ratio | 1.49 | 0.90 | 1.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩354.38 Billion | ₩213.48 Billion | ₩192.79 Billion |
Boryung Pharm - Advanced Valuation Insights
This section examines the relationship between Boryung Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 27.2% |
| Total Assets | ₩1.16 Trillion |
| Market Capitalization | $474.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Boryung Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Boryung Pharm's assets grew by 27.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Boryung Pharm (2009–2024)
The table below shows the annual total assets of Boryung Pharm from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.16 Trillion ≈ $788.89 Million |
+27.15% |
| 2023-12-31 | ₩915.51 Billion ≈ $620.43 Million |
+2.59% |
| 2022-12-31 | ₩892.39 Billion ≈ $604.76 Million |
+7.69% |
| 2021-12-31 | ₩828.64 Billion ≈ $561.56 Million |
+27.88% |
| 2020-12-31 | ₩647.99 Billion ≈ $439.14 Million |
+27.65% |
| 2019-12-31 | ₩507.63 Billion ≈ $344.01 Million |
+12.80% |
| 2018-12-31 | ₩450.02 Billion ≈ $304.97 Million |
+11.80% |
| 2017-12-31 | ₩402.52 Billion ≈ $272.78 Million |
+1.16% |
| 2016-12-31 | ₩397.90 Billion ≈ $269.65 Million |
+45.75% |
| 2012-12-31 | ₩273.01 Billion ≈ $185.01 Million |
+4.05% |
| 2011-12-31 | ₩262.39 Billion ≈ $177.82 Million |
+6.72% |
| 2010-12-31 | ₩245.86 Billion ≈ $166.61 Million |
+39.07% |
| 2009-12-31 | ₩176.79 Billion ≈ $119.80 Million |
-- |
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more